Have a feature idea you'd love to see implemented?
Let us know!
CASI CASI Pharmaceuticals Inc
Price (delayed)
$5.83
Market cap
$77.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.03
Enterprise value
$86.93M
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is
Highlights
CASI Pharmaceuticals's net income has increased by 34% YoY
CASI's EPS is up by 33% year-on-year
The equity has dropped by 72% year-on-year
CASI's gross profit has shrunk by 53% YoY
Key stats
What are the main financial stats of CASI
Market
Valuations
Earnings
Shares outstanding
13.38M
Market cap
$77.99M
Enterprise value
$86.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.65
Price to sales (P/S)
3.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.76
Revenue
$23.1M
EBIT
-$27.15M
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
-$2.03
Free cash flow per share
N/A
Book value per share
$0.67
Revenue per share
$1.72
TBVPS
$3.71
Total assets
$51.27M
Total liabilities
$42.25M
Debt
$18.47M
Equity
$9.02M
Working capital
$27.61M
Debt to equity
2.05
Current ratio
3.88
Quick ratio
2.14
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
56.8%
Net margin
-117.7%
Operating margin
-116.8%
Return on assets
-42.1%
Return on equity
-131.9%
Return on invested capital
-55.5%
Return on capital employed
-65.1%
Return on sales
-117.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CASI stock price
How has the CASI Pharmaceuticals stock price performed over time
Intraday
6%
1 week
7.37%
1 month
5.81%
1 year
74.03%
YTD
-18.58%
QTD
-5.36%
Financial performance
How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$23.1M
Gross profit
$13.12M
Operating income
-$26.98M
Net income
-$27.18M
Gross margin
56.8%
Net margin
-117.7%
CASI's gross profit has shrunk by 53% YoY
CASI's revenue is down by 47% YoY
CASI Pharmaceuticals's net income has increased by 34% YoY
CASI's operating margin is down by 31% YoY
Growth
What is CASI Pharmaceuticals's growth rate over time
Valuation
What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.65
P/S
3.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.76
CASI's EPS is up by 33% year-on-year
The stock's P/B is 140% above its last 4 quarters average of 3.6
The equity has dropped by 72% year-on-year
CASI's P/S is 78% above its last 4 quarters average of 1.9 but 71% below its 5-year quarterly average of 11.8
CASI's revenue is down by 47% YoY
Efficiency
How efficient is CASI Pharmaceuticals business performance
The return on equity has declined by 43% year-on-year
CASI's return on sales is down by 31% year-on-year
CASI's ROIC is up by 30% YoY
Dividends
What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CASI.
Financial health
How did CASI Pharmaceuticals financials performed over time
The total assets is 21% greater than the total liabilities
CASI's total liabilities has soared by 76% YoY
CASI Pharmaceuticals's quick ratio has plunged by 50% YoY
The debt is 105% greater than the equity
The equity has dropped by 72% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.